Beckman Coulter, Hach Company Combine Particle Characterization and Counting Businesses - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Beckman Coulter, Hach Company Combine Particle Characterization and Counting Businesses

Beckman Coulter Life Sciences, a Danaher Corporation-owned life science company, is combining its particle characterization business with the particle counting business from Hach Company, another Danaher company. The move brings together Beckman Coulter’s knowledge in cell viability, particle sizing, and particle analysis with Hach’s experience in air and liquid particle counting, according to a Beckman Coulter press statement.

In some countries, the transition is subject to completing consultation and/or information with certain employee representative bodies. Personnel from the particle counting business of Hach will transition into the Beckman Coulter Life Sciences business to work with the Beckman Coulter particle characterization team.

Source: Beckman Coulter Life Sciences


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here